Aptevo Therapeutics Files 8-K
Ticker: APVO · Form: 8-K · Filed: Nov 20, 2024 · CIK: 1671584
| Field | Detail |
|---|---|
| Company | Aptevo Therapeutics Inc. (APVO) |
| Form Type | 8-K |
| Filed Date | Nov 20, 2024 |
| Risk Level | low |
| Pages | 1 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: regulatory-filing, 8-K
Related Tickers: APVO
TL;DR
APVO filed an 8-K, check for updates.
AI Summary
Aptevo Therapeutics Inc. filed an 8-K on November 20, 2024, to report other events and financial statements. The filing does not contain specific details about new events or financial figures within the provided text.
Why It Matters
This filing indicates a regulatory update from Aptevo Therapeutics, which could contain important information for investors regarding company events or financial status.
Risk Assessment
Risk Level: low — The filing is a standard 8-K for reporting events and exhibits, with no immediate indication of significant negative news.
Key Players & Entities
- Aptevo Therapeutics Inc. (company) — Registrant
- November 20, 2024 (date) — Date of earliest event reported
- 206-838-0500 (phone_number) — Registrant's Telephone Number
FAQ
What is the primary purpose of this 8-K filing for Aptevo Therapeutics Inc.?
The primary purpose of this 8-K filing is to report 'Other Events' and 'Financial Statements and Exhibits' as of November 20, 2024.
What is the exact date of the earliest event reported in this filing?
The date of the earliest event reported is November 20, 2024.
What is the principal executive office address for Aptevo Therapeutics Inc.?
The principal executive office address is 2401 4th Avenue Suite 1050, Seattle, Washington 98121.
What is the Commission File Number for Aptevo Therapeutics Inc.?
The Commission File Number for Aptevo Therapeutics Inc. is 001-37746.
What is the Standard Industrial Classification code for Aptevo Therapeutics Inc.?
The Standard Industrial Classification code for Aptevo Therapeutics Inc. is PHARMACEUTICAL PREPARATIONS [2834].
Filing Stats: 448 words · 2 min read · ~1 pages · Grade level 11.3 · Accepted 2024-11-20 08:45:07
Key Financial Figures
- $0.001 — nge on which registered Common Stock, $0.001 par value APVO The Nasdaq Stock Mar
Filing Documents
- apvo-20241120.htm (8-K) — 41KB
- apvo-ex99_1.htm (EX-99.1) — 26KB
- img237228349_0.jpg (GRAPHIC) — 4KB
- 0000950170-24-129018.txt ( ) — 195KB
- apvo-20241120.xsd (EX-101.SCH) — 25KB
- apvo-20241120_htm.xml (XML) — 5KB
01 Other Events
Item 8.01 Other Events. On November 20, 2024, Aptevo Therapeutics Inc. ("Aptevo" or the "Company") announced that the first patient dosed in Aptevo's ongoing RAINIER trial achieved a 90% reduction in leukemic blasts within the first 30 days of treatment, supporting the continued overall efficacy trend seen in prior mipletamig AML studies. A copy of the press release is attached is attached hereto as Exhibit 99.1 and is incorporated by reference herein.
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 99.1 Press Release dated November 20, 2024. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. APTEVO THERAPEUTICS INC. Date: November 20, 2024 By: /s/ Marvin L. White President and Chief Executive Officer